Retatrutide and Tirzepatide from ₱750 a vial in 25, 50 and 100 packs. Split it with friends or resell it under your own label.From ₱750 a vial: 25, 50 and 100 packs for group buys and resellers.See bulk prices →
Weight loss · Compound
Retatrutide
An investigational triple agonist of the GLP-1, GIP and glucagon receptors, developed by Eli Lilly and studied for obesity and type 2 diabetes.
Philippines Peptides editorial deskUpdated Trial data checked 23 September 202620 min read9 sources
Short answer
Retatrutide is an investigational triple agonist from Eli Lilly. In TRIUMPH-1, a phase 3 trial of 2,339 adults with obesity or overweight, body weight fell 28.3% at 80 weeks on the highest-dose arm, against 2.2% on placebo. As of 23 September 2026 it is approved nowhere, including the Philippines; Lilly plans a US filing in Q1 2027.
2:10
Video guide: Retatrutide in the Philippines: Status, Trials, Sourcing (2:10)Video transcript
Searching for retatrutide in the Philippines? Here is the short answer, checked September 2026. Retatrutide is an investigational peptide from Eli Lilly that activates three hormone receptors: GLP-1, GIP and glucagon. It is not registered with FDA Philippines, and no regulator anywhere has approved it. No pharmacy here sells it, and no pharmaceutical version exists, so pharmacy grade claims are mislabelled. In TRIUMPH-1, a phase 3 trial of 2,339 adults without diabetes, body weight fell 28.3% at 80 weeks on the highest-dose arm, against 2.2% on placebo. The most common side effects were nausea, diarrhoea and constipation. Nausea was reported in 28.6% to 42.4% of participants. 11.3% on the highest-dose arm stopped because of side effects, against 4.9% on placebo. Dysesthesia, a change in skin sensation, appeared in every phase 3 trial. What is sold here is research material: not approved for human use, and sold for research only. Our partner and supplier, Primara Labs, lists a retatrutide vial at [₱3,390 for the 20 mg vial], or [₱2,076] each in a 10 pack. That is about [₱170] per mg, or [₱104] in a 10 pack. Retatrutide batch RETA-4728-A was tested by Janoshik for bacterial endotoxin. Batch reports are published at primaralabs.com/coa as they are issued. Every vial order includes bacteriostatic water, insulin syringes and alcohol pads. Metro Manila orders before noon arrive the same day, provinces ship by J&T, and there is a 60-day money-back guarantee. Read the full guide on Philippines Peptides, then see retatrutide at Primara Labs and order on WhatsApp. [Figures in square brackets corrected on 3 November 2026 from Primara's current catalogue: the narration gives the price of the 15 mg retatrutide vial, retired on 12 October 2026.]
Body weight fell on the 12 mg arm in TRIUMPH-1, an 80-week phase 3 trial of 2,339 adults with obesity, or overweight with at least one weight-related condition, without diabetes, against 2.2% on placebo
28.3%
Completed trials with a reported result in the Research Desk dataset
5
US FDA status, checked 23 September 2026
Investigational
The strongest evidence found for Retatrutide comes from phase 3 human trials, and every finding below carries its evidence level.
Availability in the Philippines
Buying Retatrutide in the Philippines
Availability
Not approved by any regulator. US FDA status: investigational. A search of the FDA Philippines verification portal on 23 September 2026 returned no registered product.
What is Retatrutide
Retatrutide (LY3437943) is an investigational peptide from Eli Lilly that activates three hormone receptors: GLP-1, GIP and glucagon. Its receptor pharmacology and first human data were published in 2022 (Coskun et al., Cell Metabolism 2022).
In TRIUMPH-1, a phase 3 trial of 2,339 adults with obesity or overweight without diabetes, body weight fell by 28.3% at 80 weeks on the highest-dose arm, against 2.2% on placebo. Every completed trial is set out below, next to the side effects each reported.
It is not approved anywhere. Sponsor plans a US Biologics License Application submission in Q1 2027, according to Lilly's release of 23 July 2026. Its status by regulator is on the regulatory status page.
How it works
GLP-1 receptor: the same target as semaglutide. GLP-1 receptor activation slows stomach emptying, increases insulin release when blood sugar is high and reduces appetite.
GIP receptor: the second target tirzepatide shares. GIP also acts on insulin release; how much it adds to weight loss in people is still studied.
Glucagon receptor: the target that distinguishes retatrutide. In the preclinical and early clinical work reported in the discovery paper, adding glucagon receptor activity increased energy expenditure (Coskun et al., 2022). Energy expenditure has not been an endpoint in any TRIUMPH readout, so its contribution in people is not measured.
Benefits studied
Body-weight reduction
Phase 3 human
TRIUMPH-1, a phase 3 trial of 2,339 adults with obesity or overweight and no diabetes, recorded an average 28.3% fall in body weight on the 12 mg arm after 80 weeks, against 2.2% on placebo. Source: Eli Lilly topline release, 21 May 2026
Blood sugar control
Phase 3 human
TRIUMPH-2, a phase 3 trial in adults with type 2 diabetes and excess weight, measured A1C falls of 1.4, 1.6 and 1.5 points across the 4, 9 and 12 mg arms over 80 weeks, from a 7.7% baseline, against 0.2 on placebo. Source: Eli Lilly topline release, 23 July 2026
Body-weight reduction with type 2 diabetes
Phase 3 human
In the 1,152 adults with type 2 diabetes enrolled in TRIUMPH-2 (phase 3), body weight fell an average 20.8% on 12 mg over 80 weeks, against 4.0% on placebo. Source: Eli Lilly topline release, 23 July 2026
Body-weight reduction with cardiovascular disease
Phase 3 human
TRIUMPH-3 (phase 3) enrolled 1,949 adults with a BMI of 35 or more and established cardiovascular disease; body weight fell an average 22.6% on 12 mg over 80 weeks, against 3.2% on placebo. Source: Eli Lilly topline release, 23 July 2026
Knee osteoarthritis pain
Phase 3 human
TRIUMPH-4, a 68-week phase 3 trial in adults with excess weight and knee osteoarthritis, reported WOMAC pain falls of 4.5 and 4.4 points on the 9 and 12 mg arms from a baseline of 6.0, against 2.4 on placebo. Source: Eli Lilly topline release, 11 December 2025
Side effects reported
TRIUMPH-1, an 80-week phase 3 trial of 2,339 adults with obesity, or overweight with at least one weight-related condition, without diabetes, reported:
Adverse events in TRIUMPH-1, share of participants
Discontinuation for adverse events: 3.8%, 11.6% and 7.7% on the 4, 9 and 12 mg arms, against 4.9% on placebo.
Diarrhoea: 27.4%, 33.5% and 33.6% on the 4, 9 and 12 mg arms, against 13.2% on placebo.
Nausea: 13.7%, 20.8% and 28% on the 4, 9 and 12 mg arms, against 8% on placebo.
Constipation: 14%, 16.2% and 16.8% on the 4, 9 and 12 mg arms, against 9.4% on placebo.
Decreased appetite: 5.8%, 12.3% and 17.1% on the 4, 9 and 12 mg arms, against 4.5% on placebo.
Vomiting: 5.5%, 10.2% and 15.7% on the 4, 9 and 12 mg arms, against 4.2% on placebo.
Dysesthesia: 4.5%, 5.6% and 7.3% on the 4, 9 and 12 mg arms, against 0.7% on placebo.
Urinary tract infection: 3.8%, 6.3% and 8% on the 4, 9 and 12 mg arms, against 6.6% on placebo.
TRIUMPH-3, an 80-week phase 3 trial of 1,949 adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes, reported:
Adverse events in TRIUMPH-3, share of participants
Discontinuation for adverse events: 12.2% and 18.2% on the 9 and 12 mg arms, against 4% on placebo.
Nausea: 38.1% and 43.2% on the 9 and 12 mg arms, against 10.7% on placebo.
Diarrhoea: 34.7% and 33.1% on the 9 and 12 mg arms, against 13.4% on placebo.
Constipation: 21.8% and 25% on the 9 and 12 mg arms, against 8.7% on placebo.
Vomiting: 20.4% and 20.9% on the 9 and 12 mg arms, against 0% on placebo.
Decreased appetite: 19% and 18.2% on the 9 and 12 mg arms, against 9.4% on placebo.
Dysesthesia: 8.8% and 20.9% on the 9 and 12 mg arms, against 0.7% on placebo.
What the trials found
In TRIUMPH-1, an 80-week phase 3 trial of 2,339 adults with obesity, or overweight with at least one weight-related condition, without diabetes, body weight fell by 19%, 25.9% and 28.3% on the 4 mg, 9 mg and 12 mg arms, against 2.2% on placebo. Source · Registry
Completed trials of Retatrutide with a reported result. Outcome: body weight
Trial and population
n
Weeks
Change by arm
Comparator
Source
TRIUMPH-1 · Phase 3Adults with obesity, or overweight with at least one weight-related condition, without diabetes
Body weight change on the highest-dose arm against placebo, Retatrutide trials
TRIUMPH-180 weeks, phase 3
−28.3% (12 mg)
−2.2% (placebo)
TRIUMPH-280 weeks, phase 3
−20.8% (12 mg)
−4% (placebo)
TRIUMPH-380 weeks, phase 3
−22.6% (12 mg)
−3.2% (placebo)
TRIUMPH-468 weeks, phase 3
−28.7% (12 mg)
−2.1% (placebo)
Retatrutide phase 2 (Jastreboff)48 weeks, phase 2
−24.2% (12 mg)
−2.1% (placebo)
Body weight change on the highest-dose arm against placebo, Retatrutide trials
Trial
Highest-dose arm
Comparator
TRIUMPH-1
12 mg −28.3%
Placebo −2.2%
TRIUMPH-2
12 mg −20.8%
Placebo −4%
TRIUMPH-3
12 mg −22.6%
Placebo −3.2%
TRIUMPH-4
12 mg −28.7%
Placebo −2.1%
Retatrutide phase 2 (Jastreboff)
12 mg −24.2%
Placebo −2.1%
Each pair is one trial: the highest-dose arm (dark) and the comparator (light). Full results and arms are in the table above.
The same figures as sentences
In TRIUMPH-2, an 80-week phase 3 trial of 1,152 adults with type 2 diabetes and obesity or overweight, body weight fell by 12.7%, 19.1% and 20.8% on the 4 mg, 9 mg and 12 mg arms, against 4% on placebo. Source · Registry
In TRIUMPH-3, an 80-week phase 3 trial of 1,949 adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes, body weight fell by 21.6% and 22.6% on the 9 mg and 12 mg arms, against 3.2% on placebo. Source · Registry
In TRIUMPH-4, a 68-week phase 3 trial of 445 adults with obesity or overweight and knee osteoarthritis, without diabetes, body weight fell by 26.4% and 28.7% on the 9 mg and 12 mg arms, against 2.1% on placebo. Source · Registry
In Retatrutide phase 2 (Jastreboff), a 48-week phase 2 trial of 338 adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition, body weight fell by 8.7%, 17.1%, 22.8% and 24.2% on the 1 mg, 4 mg (pooled), 8 mg (pooled) and 12 mg arms, against 2.1% on placebo. Source · Registry
TRIUMPH-5, phase 3, in adults who have obesity. Measuring: compared with tirzepatide.
TRIUMPH-6, phase 3, in adults with obesity. Measuring: maintenance of weight reduction.
TRIUMPH-7, phase 3, in adults with obesity or overweight and chronic low back pain.
TRIUMPH-8, phase 3, in adults with obesity or overweight.
TRIUMPH-9, phase 3, in adults without type 2 diabetes who have obesity or overweight.
TRIUMPH-OUTCOMES, phase 3, in adults living with obesity. Measuring: cardiovascular and kidney outcomes.
Dysesthesia
Dysesthesia is an altered or unpleasant skin sensation, such as tingling, burning or sensitivity to touch. It is the adverse event that sets the phase 3 retatrutide programme apart from the phase 2 trial, which did not report it as a distinct event (Jastreboff, NEJM 2023).
Dysesthesia by trial, share of participants
Trial
Participants
Weeks
Retatrutide arms
Placebo
TRIUMPH-1
2,339
80
4 mg 5.1%9 mg 12.3%12 mg 12.5%
0.9%
TRIUMPH-2
1,152
80
4 mg 4.5%9 mg 5.6%12 mg 7.3%
0.7%
TRIUMPH-3
1,949
80
9 mg 6.4%12 mg 6.4%
1.3%
TRIUMPH-4
445
68
9 mg 8.8%12 mg 20.9%
0.7%
The same figures as sentences
TRIUMPH-1 (2,339 participants, 80 weeks): Dysesthesia: 5.1%, 12.3% and 12.5% on the 4, 9 and 12 mg arms, against 0.9% on placebo.
TRIUMPH-2 (1,152 participants, 80 weeks): Dysesthesia: 4.5%, 5.6% and 7.3% on the 4, 9 and 12 mg arms, against 0.7% on placebo.
TRIUMPH-3 (1,949 participants, 80 weeks): Dysesthesia: 6.4% and 6.4% on the 9 and 12 mg arms, against 1.3% on placebo.
TRIUMPH-4 (445 participants, 68 weeks): Dysesthesia: 8.8% and 20.9% on the 9 and 12 mg arms, against 0.7% on placebo.
Lilly described the TRIUMPH-4 events as generally mild and said they rarely led to discontinuation (Lilly, 11 December 2025), and described the TRIUMPH-1 events as generally mild to moderate, with most resolving during continued treatment (Lilly, 21 May 2026). The rate did not rise with every dose step in every trial: in TRIUMPH-3 it was the same on both arms. The mechanism has not been established.
Heart rate
In the phase 2 trial of 338 adults with obesity over 48 weeks, heart rate rose with dose, peaked at about 24 weeks and declined afterwards (Jastreboff, NEJM 2023). None of Lilly's TRIUMPH releases reported heart rate.
A 2026 network meta-analysis of 12 randomised trials with 15,313 adults with overweight or obesity without diabetes estimated a mean heart-rate increase against control of 3.46 beats per minute for retatrutide (1.74 to 5.18), against 3.35 for semaglutide and 2.05 for tirzepatide (Eur J Med Res 2026). TRIUMPH-OUTCOMES, a phase 3 trial of cardiovascular and kidney outcomes, is still running.
Hair loss
Lilly's TRIUMPH-1 release, covering 2,339 participants over 80 weeks, did not list hair loss among its reported adverse events (Lilly, 21 May 2026).
In the same drug class, a 2026 systematic review found alopecia reported in 7% of tirzepatide participants against 1.4% on placebo in one SURMOUNT report, and concluded that rapid weight loss, rather than direct drug toxicity, is the likely driver, through telogen effluvium, a temporary shedding that follows a physical stress (Gupta et al., Science Progress 2026). That review covers tirzepatide and semaglutide, not retatrutide.
Half-life and liver fat
In a phase 1b trial in people with type 2 diabetes, retatrutide's half-life was approximately six days (Urva et al., Lancet 2022). That is the reason the trials give it once a week. The phase 2 publication and the phase 3 releases do not restate the figure.
A phase 2a trial in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) reported large reductions in liver fat (Sanyal et al., Nature Medicine 2024). Liver fat has not been a reported endpoint of the phase 3 TRIUMPH readouts.
Regulatory status
FDA Philippines
No registered drug product found on the FDA verification portal.
US FDA
InvestigationalEli Lilly's release of 23 July 2026 describes retatrutide as investigational. Drugs@FDA returned no approved application.
European Medicines Agency
No record foundNo row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
Next milestone
Sponsor plans a US Biologics License Application submission in Q1 2027
How Philippine registration and prescription rules work, and what an unregistered product is under the law, is covered in the regulation hub, and every compound's status side by side is on the status page. This is general information, not legal advice.
Batch reports
Retatrutide batch reports from our partner and supplier
Janoshik-tested for bacterial endotoxin, batch RETA-4728-A
Retatrutide. Laboratory: Janoshik. Test: Bacterial endotoxin (LAL). Analysed 21 September 2026. Result as printed: 6.066 EU per vial.
This report covers bacterial endotoxin only. It does not establish identity or purity.
From the batch-report dataset Primara Labs publishes, updated 23 September 2026. The store’s own list: Primara Labs batch reports.
Who should not use Retatrutide
FAQ
What is retatrutide?
Retatrutide is an investigational peptide from Eli Lilly that activates the GLP-1, GIP and glucagon receptors. It is being studied for obesity and type 2 diabetes in the phase 3 TRIUMPH programme and is not approved anywhere.
What did the TRIUMPH trials find?
In TRIUMPH-1, a phase 3 trial of 2,339 adults with obesity or overweight without diabetes, body weight fell by 28.3% at 80 weeks on the highest-dose arm, against 2.2% on placebo. 5 completed trials with reported results are listed on this page, each with its population and duration.
What are the most common side effects of retatrutide in the trials?
In TRIUMPH-1 the most frequently reported adverse events were nausea, diarrhoea, constipation, vomiting and urinary tract infection. 4.1%, 6.9% and 11.3% of participants on the 4 mg, 9 mg and 12 mg arms stopped treatment because of adverse events, against 4.9% on placebo. Dysesthesia, a change in skin sensation, was reported in every phase 3 trial.
What is retatrutide dysesthesia?
Dysesthesia is an altered or unpleasant skin sensation, such as tingling or burning. It was reported in all four TRIUMPH readouts and was not reported as a distinct event in the phase 2 trial. Lilly described the events as generally mild. The rate for each trial and arm is on this page.
Does retatrutide raise heart rate?
In the phase 2 trial, heart rate rose with dose, peaked at about 24 weeks and declined afterwards. A 2026 network meta-analysis estimated a mean increase of 3.46 beats per minute against control for retatrutide, against 3.35 for semaglutide and 2.05 for tirzepatide. The TRIUMPH releases did not report heart rate.
Does retatrutide cause hair loss?
Lilly’s TRIUMPH-1 release did not list hair loss among its reported adverse events. In the same drug class, a 2026 systematic review linked alopecia to rapid weight loss through telogen effluvium rather than to the drugs directly; that review did not cover retatrutide.
What is the half-life of retatrutide?
Approximately six days, measured in a phase 1b trial in people with type 2 diabetes (Urva et al., Lancet 2022). That is why the trials give it once a week.
Is retatrutide registered in the Philippines?
No. A search of the FDA Philippines verification portal on 23 September 2026 returned no registered retatrutide product, and no regulator anywhere has approved it. This is general information, not legal advice.
Where to get Retatrutide in the Philippines
Finished reading and not sure where a 90-day plan would start? Longevity Manila builds one around a single goal, then hands the list to our partner and supplier, Primara Labs.
Retatrutide is not sold by any Philippine pharmacy or hospital, because no retatrutide product is registered. Availability and legal status in the Philippines are covered in the Retatrutide Philippines guide.
Retatrutide phase 1b: pharmacokinetics in type 2 diabetesTrial
Urva S et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial." Lancet 2022;400:1869-1881.
Sanyal AJ et al. "Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial." Nat Med 2024;30:2037-2048.
Coskun T et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycaemic control and weight loss: From discovery to clinical proof of concept." Cell Metab 2022;34(9):1234-1247.e9.
This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.
In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.
